jurpsy schreef op 20 juni 2016 20:27:
[...]
Lower;
* P. Calias is al maanden geleden (jaarwisseling) netjes aan de deur gezet.
...........Mr. Calias left the company in early 2016 after setting up a sound R&D function in France and Netherlands for Pharming.
This R&D team is now continuing formal work on two major projects in Pompe disease and Fabry’s disease, with others in early stage development.
*Subcutane versie:...
Bij de FDA & EMA lopen reeds gesprekken hierover.
( Er wordt getracht een versnelde procedure te verkrijgen.)
............. Early experiments have shown that a good formulation of RUCONEST® suitable for subcutaneous delivery is possible, and this project is now fully active. The new form of RUCONEST® will need to be tested in a clinical setting, which is expected to be starting in early 2017.